[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing
Current Oncology · 2026
DOI: 10.3390/curroncol33100624 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2026. Verfasst von Carlo Buonerba und 1 weiteren Autor:innen. Beteiligte Einrichtung: Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Dipeptides, Lutetium, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introducing [177Lu]Lu-PSMA-617 into metastatic hormone-sensitive prostate cancer (mHSPC) raises questions about patient selection and treatment sequencing. This non-systematic narrative review examines PSMAddition alongside evidence on alternative treatments, prostate-specific membrane antigen (PSMA) imaging, safety, and subsequent therapy. In the peer-reviewed analysis, with a data cutoff of 13 January 2025, adding radioligand therapy to androgen-deprivation therapy and an investigator-selected androgen receptor pathway inhibitor improved radiographic progression-free survival (hazard ratio 0.72; 95% confidence interval 0.58–0.90). Overall survival was immature and did not meet the prespecified interim significance threshold (hazard ratio 0.84; 95% confidence interval 0.63–1.13). A subsequent non-peer-reviewed sponsor update supported the radiographic findings, although the updated analysis was not controlled for type I error and overall survival remained immature. Radioligand intensification increased grade ≥3 adverse events (51% versus 43%). Prespecified composite quality-of-life and pain endpoints showed no statistically significant differences, although their interpretation is limited by the inclusion of progression or death. Control-arm crossover after progression was optional. Direct mHSPC evidence is distinguished from contextual castration-resistant evidence. Neither a preferred hormonal partner nor superiority over docetaxel-containing triplet therapy has been established. A non-prescriptive five-domain framework integrates target expression, disease characteristics, patient fitness, subsequent treatment options, and delivery capacity to support multidisciplinary assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy.
- School of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
ORCID-Profile: Giuseppe Di Lorenzo
Zitieren
APA
Buonerba, C., & Di Lorenzo, G. (2026). [177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing. Current Oncology. https://doi.org/10.3390/curroncol33100624
Vancouver
Buonerba C, Di Lorenzo G. [177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing. Current Oncology. 2026. doi:10.3390/curroncol33100624
BibTeX
@article{Buonerba2026,
author = {Buonerba, Carlo and Di Lorenzo, Giuseppe},
title = {[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100624}
}
EUVIMED